Investigating an existing CVRM medicine as a potential treatment for COVID-19

In partnership with Saint Luke’s Mid America Heart Institute, we are initiating the second new Phase III clinical trial in less than two weeks to address the COVID-19 pandemic. One of our existing medicines will be evaluated to see whether it might reduce the risk of disease progression and new or worsened organ dysfunction in patients hospitalised with COVID-19 who also have cardiovascular (CV), metabolic or kidney risk factors and are at risk of developing serious complications.

Patients with COVID-19 who also have an underlying cardiometabolic disease appear to be at the higher risk of serious complications or death. Through this new trial, we hope to decrease the severity of illness, and reduce the risk of cardiovascular, respiratory and kidney failure, which are common in patients with COVID-19.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “AstraZeneca is committed to finding new solutions to fight COVID-19 by investigating the application of our new and existing medicines. With this new trial, we aim to test whether our medicine can reduce the risk of serious complications such as new or worsened organ dysfunction in those patients with pre-existing health conditions, a critical goal when treating COVID-19.”

Given how quickly the condition of COVID-19 patients can deteriorate when complications occur, the AstraZeneca team in collaboration with Saint Luke’s Mid America Heart Institute moved swiftly to design and initiate the trial. These incredibly fast timelines speak to the unified purpose and the sheer determination of this team and its collaborators to do the right thing.


Veeva ID: Z4-23961
Date of preparation: April 2020